Chronic kidney disease (CKD) is associated with multiple adverse outcomes. This study quantifies the mortality risk associated with CKD, characterized by an estimated glomerular filtration rate (eGFR) of <60 ml/min/1.73m2, utilizing de-identified electronic health record data from the Optum Labs Data Warehouse in 4,788,021 men and 5,766,551 women. Mortality rates were estimated per 1000 person-years by sex and 5-year age group and absolute risk difference were estimated as attributable risk per 1000 person-years. Elevated mortality rates were seen among individuals with reduced eGFR for all age groups and for both men and women. The analysis revealed a linear decline in the incidence rate ratios of mortality with advancing age, while attributable risks increased due to the marked increase in mortality with age. These sex-specific risk estimates from a large sample enhance previous findings and are crucial for refining global burden of disease metrics and health economic evaluations of CKD.

The authors have declared no competing interest.

The CKD Prognosis Consortium (CKD-PC) Data Coordinating Center is funded in part by a program grant from the US National Kidney Foundation and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100446).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The institutional review board at the New York University Grossman School of Medicine, New York, NY, USA (#i23-00919) gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Under agreement with the participating cohorts, CKD-PC cannot share individual data with third parties. Inquiries regarding specific analyses should be made to ckdpcnyulangone.org.